Detection of Botulinum Neurotoxin A (BoNT/A) Enzymatic Activity by Pregnancy Test Strips Based on HCG-modified Magnetic Nanoparticles

Overview

Journal Mikrochim Acta

Specialties Biotechnology
Chemistry

Date 2024 Jan 29

PMID 38286853

Authors

Xinxin Zhou

Min Qi

Minghui Yang

Affiliations

Soon will be listed here.

Abstract

The detection of botulinum neurotoxin A (BoNT/A) endopeptidase activity by pregnancy test paper based on human chorionic gonadotropin (hCG)-functionalized peptide-modified magnetic nanoparticles (MNs) is described for the first time. HCG-functionalized SNAP-25 peptide substrate with hydrolysis recognition sites was optimally designed. HCG can be recognized by pregnancy test strips. BoNT/A light chain (BoNT-LcA) is the central part of the endopeptidase function in holotoxin, which can specifically hydrolyze SNAP-25 peptide to release the hCG-peptide probe, and the hCG-peptide probe released can be quantitatively detected by pregnancy test strips, achieving indirect determination of BoNT/A. By quantifying the T-line color intensity of test strips, the visual detection limit for BoNT-LcA is 12.5 pg/mL, and the linear range of detection for BoNT-LcA and BoNT/A holotoxin was 100 pg/mL to 1 ng/mL and 25 to 250 ng/mL. The ability of the method to quantify BoNT/A was validated in human serum samples. This method shows the potential for sensitive detecting BoNT/A and has prospects for the diagnosis and prognosis of clinical botulism.

References

Schmidt J, Bostian K . Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem. 1997; 16(1):19-26. DOI: 10.1023/a:1026386710428. View

Frisk M, Tepp W, Johnson E, Beebe D . Self-assembled peptide monolayers as a toxin sensing mechanism within arrayed microchannels. Anal Chem. 2009; 81(7):2760-7. PMC: 2760437. DOI: 10.1021/ac802707u. View

Lamanna C . The most poisonous poison. Science. 1959; 130(3378):763-72. DOI: 10.1126/science.130.3378.763. View

Janik E, Ceremuga M, Saluk-Bijak J, Bijak M . Biological Toxins as the Potential Tools for Bioterrorism. Int J Mol Sci. 2019; 20(5). PMC: 6429496. DOI: 10.3390/ijms20051181. View

Sugiyama H . Clostridium botulinum neurotoxin. Microbiol Rev. 1980; 44(3):419-48. PMC: 373187. DOI: 10.1128/mr.44.3.419-448.1980. View

Chalk C, Benstead T, Pound J, Keezer M . Medical treatment for botulism. Cochrane Database Syst Rev. 2019; 4:CD008123. PMC: 6468196. DOI: 10.1002/14651858.CD008123.pub4. View

Cai S, Singh B, Sharma S . Botulism diagnostics: from clinical symptoms to in vitro assays. Crit Rev Microbiol. 2007; 33(2):109-25. DOI: 10.1080/10408410701364562. View

Smith L . Botulism and vaccines for its prevention. Vaccine. 2009; 27 Suppl 4:D33-9. DOI: 10.1016/j.vaccine.2009.08.059. View

Dressler D . Clinical applications of botulinum toxin. Curr Opin Microbiol. 2012; 15(3):325-36. DOI: 10.1016/j.mib.2012.05.012. View

10.

Arnon S, Schechter R, INGLESBY T, Henderson D, Bartlett J, Ascher M . Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001; 285(8):1059-70. DOI: 10.1001/jama.285.8.1059. View

11.

Gul N, Smith L, Ahmed S . Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PLoS One. 2010; 5(9):e12872. PMC: 2943925. DOI: 10.1371/journal.pone.0012872. View

12.

Ahmed S, McPhie P, Smith L . Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically active. Biochemistry. 2003; 42(43):12539-49. DOI: 10.1021/bi030062c. View

13.

Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T . The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006; 580(8):2011-4. DOI: 10.1016/j.febslet.2006.02.074. View

14.

Pirazzini M, Rossetto O, Eleopra R, Montecucco C . Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017; 69(2):200-235. PMC: 5394922. DOI: 10.1124/pr.116.012658. View

15.

Thirunavukkarasu N, Johnson E, Pillai S, Hodge D, Stanker L, Wentz T . Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance. Front Bioeng Biotechnol. 2018; 6:80. PMC: 6024544. DOI: 10.3389/fbioe.2018.00080. View

16.

capek P, Dickerson T . Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel). 2011; 2(1):24-53. PMC: 3206617. DOI: 10.3390/toxins2020024. View

17.

Rust A, Doran C, Hart R, Binz T, Stickings P, Sesardic D . A Cell Line for Detection of Botulinum Neurotoxin Type B. Front Pharmacol. 2017; 8:796. PMC: 5684488. DOI: 10.3389/fphar.2017.00796. View

18.

Xavier B, Perobelli R, Walter M, da Silva F, Dalmora S . Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays. Toxins (Basel). 2019; 11(1). PMC: 6356430. DOI: 10.3390/toxins11010035. View

19.

Rasooly R, Do P . Development of an in vitro activity assay as an alternative to the mouse bioassay for Clostridium botulinum neurotoxin type A. Appl Environ Microbiol. 2008; 74(14):4309-13. PMC: 2493148. DOI: 10.1128/AEM.00617-08. View

20.

Ng A, Uddayasankar U, Wheeler A . Immunoassays in microfluidic systems. Anal Bioanal Chem. 2010; 397(3):991-1007. DOI: 10.1007/s00216-010-3678-8. View